Long Road Ahead for Jak Program
Analyst Brian Skorney sees increased interest in inflammatory bowel disorder programs. Even with an aggressive timeline for Theravance's lead drug candidate for ulcerative colitis, the analyst expects a launch only by 2023, well after Pfizer Inc. PFE's Xeljanz, Celgene Corporation CELG's ozanimod, Gilead Sciences, Inc. GILD's filgotinib and AbbVie Inc ABBV's ABT-494.
Attrition Post Mid-Stage Worrisome
Baird noted that some of Theravance's treatment candidates, namely Velusetrag, TD-1792 and axelopran, have all been stuck in a limbo after getting into mid-stage trials. The firm cautioned that the current valuation of the company implies a higher probability of success for the company's current pipeline than is reasonable for anyone in the sector.
At the time of writing, shares of Theravance was down 12.42 percent at $32.79.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.